MedTrace Logo

Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction

NCT00222573 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46000

Last updated 2006-05-05

No results posted yet for this study

Summary

COMMIT/CCS2 is a large randomised trial of the effects of clopidogrel plus Aspirin versus Aspirin alone in acute heart disease. Patients presenting within 24 hours of the onset of suspected acute MI were potentially eligible provided they were thought to have ST elevation or other ischaemic ECG abnormality with no clear indication for, or contraindication to, trial treatment. All patients were to be given 162 mg ASA daily and, in addition, 75 mg clopidogrel daily or matching placebo for 4 weeks or until prior discharge or death. (Patients were also randomised separately in a 2 X 2 factorial design between metoprolol versus placebo.) The two main study endpoints are death and the composite outcome of death, non-fatal reinfarction or stroke during the scheduled treatment period in hospital.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

clopidogrel and metoprolol

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • University of Oxford

    lead OTHER

Principal Investigators

  • Rory Collins, Msc · University of Oxford

  • Lisheng Liu, MD · Institute of cardiovascular diseases, Fuwai hospital, Chinese academy of medical sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31
Completion
2005-02-28

Countries

  • China
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00222573 on ClinicalTrials.gov